Monoclonal Antibodies Market in Gastric and Esophageal Cancers to Reach USD 766 Mln by 2019, Says GBI Research in Its Report Available at MarketPublishers.com
In-demand research study “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” worked out by GBI Research has been recently published by Market Publishers Ltd. According to the study, the value of the overall market for mAbs in gastric and esophageal cancers is forecast to touch the USD 766 million mark by 2019.
London, UK (PRWEB) January 06, 2014
Currently, esophageal and gastric cancers are the two major types of cancer associated with the gastrointestinal tract. These kinds of cancer are usually diagnosed only at advanced and incurable stages given a late onset of symptoms. However, the diseases also demonstrate low survival rates even in the early stages. At present, the key options used to treat esophageal and gastric cancers include surgery and chemotherapy. One monoclonal antibody (mAb), namely Herceptin, is currently marketed for the use in suitable patients with advanced gastro-esophageal or gastric junction cancer.
Nowadays, the late-stage esophageal and gastric cancers pipelines include numerous promising mAbs candidates that are likely to enter the marketplace during 2014-2019. Actual market environment is regarded as rather favourable for new mAbs, with weak impact from biosimilar exposure along with high pricing patterns. The value of the overall market for mAbs in gastric and esophageal cancers is expected to touch the USD 766 million mark by 2019.
In-demand research study "Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth" worked out by GBI Research has been recently published by Market Publishers Ltd.
Title: Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Published: December, 2013
Price: US$ 3,500.00
The report is a comprehensive guide to the market for mAbs in gastric and esophageal cancers. It contains detailed diseases’ profiles, including coverage of symptoms, etiology, epidemiology, pathophysiology, risk factors, diagnosis, treatment options, etc.; highlights the historical and current development of the gastric and esophageal cancers overall pipelines, reviews the major pipeline products available, as well as uncovers vital data on the drugs that are expected to enter the market in the offing. The report traces the recent deals and strategic consolidations in the examined field, offers a profound analysis of pipeline drug clinical trials, draws up a forecast scenario of the market performance up to 2019, and also scrutinizes the impact of the expiry of key current patents on the current drugs, the emergence of new drugs, and certain changes in disease epidemiology across the main geographical markets – the US, Japan Canada, the UK, Germany, Italy, France, and Spain.
Report Features & Benefits:
- Determine and understand the unmet needs in the treatment of gastric and esophageal cancers.
- Evaluate the role of Herceptin and pinpoint the promising opportunities for other mAbs to enter the market.
- Get an idea of the pipeline scope and understand the prominent molecule types and mechanisms of action.
- Observe the trends prevailing in the field and at certain development phases.
- Assess the risks of the current and future programs for mAbs in gastric and esophageal cancers with the help of the clinical trial failure rate analysis.
- Trace the shift in clinical trial endpoints, and thus use the acquired knowledge to influence any future development programmes.
- Assess the key drivers and barriers of the market growth.
- Get an idea of how the market landscape is set to change through to 2019.
More insightful research reports by GBI Research can be found at http://marketpublishers.com/members/gbiresearch/info.html
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/01/prweb11464191.htm